Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options

Janusz Skowronek, Janusz Skowronek

Abstract

Purpose: Permanent low-dose-rate (LDR-BT) and temporary high-dose-rate (HDR-BT) brachytherapy are competitive techniques for clinically localized prostate radiotherapy. Although a randomized trial will likely never to be conducted comparing these two forms of brachytherapy, a comparative analysis proves useful in understanding some of their intrinsic differences, several of which could be exploited to improve outcomes. The aim of this paper is to look for possible similarities and differences between both brachytherapy modalities. Indications and contraindications for monotherapy and for brachytherapy as a boost to external beam radiation therapy (EBRT) are presented. It is suggested that each of these techniques has attributes that advocates for one or the other. First, they represent the extreme ends of the spectrum with respect to dose rate and fractionation, and therefore have inherently different radiobiological properties. Low-dose-rate brachytherapy has the great advantage of being practically a one-time procedure, and enjoys a long-term follow-up database supporting its excellent outcomes and low morbidity. Low-dose-rate brachytherapy has been a gold standard for prostate brachytherapy in low risk patients since many years. On the other hand, HDR is a fairly invasive procedure requiring several sessions associated with a brief hospital stay. Although lacking in significant long-term data, it possesses the technical advantage of control over its postimplant dosimetry (by modulating the source dwell time and position), which is absent in LDR brachytherapy. This important difference in dosimetric control allows HDR doses to be escalated safely, a flexibility that does not exist for LDR brachytherapy.

Conclusions: Radiobiological models support the current clinical evidence for equivalent outcomes in localized prostate cancer with either LDR or HDR brachytherapy, using current dose regimens. At present, all available clinical data regarding these two techniques suggests that they are equally effective, stage for stage, in providing high tumor control rates.

Keywords: HDR; LDR; brachytherapy; prostate cancer; seeds.

Figures

Fig. 1
Fig. 1
Differential dose volume histograms (dDVH) for 125I, 103Pd and 192Ir from average patient-derived data. Note that for the 192Ir HDR brachytherapy DVH, the dose scale is ‘percent dose’, because different dose fraction sizes can be prescribed (A). Note how heterogeneous and ‘hot’ these DVH are, particularly for 125I and 103Pd [38]

References

    1. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999;44:789–799.
    1. Porter AT, Blasko JC, Grimm PD, et al. Brachytherapy for Prostate Cancer. Cancer J Clin. 1995;45:165–178.
    1. Garbaulet A, Potter R, Mazeron JJ, et al. Brussels. 2002. The GEC ESTRO Handbook of Brachytherapy; pp. 473–480. chapter 20.
    1. Ash D, Flynn A, Battermann J, de Reijke T, et al. ESTRO/EAU/ EORTC recommendations on permanent seed implantation for localized prostate cancer. Radioth Oncol. 2000;57:315–321.
    1. Thompson I, Thrasher JB, Aus G, et al. Guidelines for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131.
    1. Horwich A, Parker C, Bangma C, et al. ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;(Suppl 5):129–133.
    1. Skowronek J, Kanikowski M, Zwierzchowski G, et al. Brachyterapia LDR w leczeniu raka gruczołu krokowego. Wspolczesna Onkol. 2009;13:316–329. In Polish.
    1. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162–200.
    1. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012;109(Suppl 1):22–29.
    1. Crook JM, Gomez-Iturriaga A, Wallace K, et al. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol. 2011;29:362–368.
    1. Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:421–432.
    1. Sylvester JE, Grimm PD, Wong J, et al. Fifteen-Year Biochemical Relapse-Free Survival, Cause-Specific Survival, and Overall Survival following I-125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience. Int J Radiat Oncol Biol Phys. 2011;81:376–381.
    1. Polascik TJ, Pound CR, DeWeese TL, et al. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology. 1998;51:884–889. discussion 889-90.
    1. Machtens S, Baumann R, Hagemann J, et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol. 2006;24:289–295.
    1. Kovacs G, Potter R, Tillmann L, et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localized prostate cancer. Radiother Oncol. 2005;74:137–148.
    1. Burchardt W, Skowronek J, Łyczek J. Samodzielna brachyterapia HDR raka gruczołu krokowego – alternatywa we wczesnym stopniu zaawansowania. Przegl Urol. 2012;4:33–38. in Polish.
    1. Chicheł A, Kanikowski M, Skowronek J, et al. Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost. J Contemp Brachytherapy. 2009;1:11–17.
    1. Seppenwoolde Y, Kolkman-Deurloo I-K, Sipkema D, et al. HDR prostate monotherapy – dosimetric effects of implant deformation due to posture change between TRUS- and CT-imaging. Radiother Oncol. 2008;86:114–119.
    1. Martin T, Baltas D, Kurek R, et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol. 2004;180:225–232.
    1. Galalae RM, Kovacs G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81–90.
    1. Kanikowski M, Skowronek J, Milecki P, et al. Brachyterapia HDR raka gruczołu krokowego. Urologia Polska. 2007;2:5–11. in Polish.
    1. Chicheł A, Kanikowski M, Skowronek J, et al. Correlation between treatment plan parameters and particular prognostic factors in prostate cancer treated with high-dose-rate brachytherapy (HDR-BT) as a boost. J Contemp Brachytherapy. 2009;1:11–17.
    1. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316–327.
    1. Demanes DJ, Rodriguez RR, Altieri GA. High dose rate prostate brachytherapy: the California Endocurietherapy (CET) Method. Radiother Oncol. 2000;57:289–296.
    1. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California Endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316.
    1. Hsu I-C, Yamada Y, Vigneault E, et al. American Brachytherapy Society Prostate High-Dose Rate Task Group. Retrieved 15-03-2010, 2010, from .
    1. Demanes DJ, Martinez AA, Ghilezan M, et al. High-Dose-Rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:1286–1292.
    1. Martinez AA, Demanes J, Vargas C, et al. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol. 2010;33:481–488.
    1. Rogers L, Rogers LI. Extended follow up of high-dose-rate brachytherapy as monotherapy for intermediate- risk prostate cancer. Brachytherapy. 2010;9(Suppl. 1):S55–S56.
    1. Yoshioka Y, Konishi K, Oh RJ, et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol. 2006;80:62–68.
    1. Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic High-Dose-Rate brachytherapy for prostate cancer: five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys. 2011;80:469–475.
    1. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61–69.
    1. Merrick GS, Zelefsky M, Sylvester K, et al. American Brachytherapy Society Prostate Low-Dose Rate Task Group. .
    1. Merrick GS, Butler WM, Galbreath RW, et al. Biochemical outcome for hormone-naive patients with Gleason score 3 + 4 versus 4 + 3 prostate cancer undergoing permanent prostate brachytherapy. Urology. 2002;60:98–103.
    1. Wallner K, Lee H, Wasserman S, et al. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys. 1997;37:565–569.
    1. Lee WR. The role of androgen deprivation therapy combined with prostate brachytherapy. Urology. 2002;60(3 Suppl 1):39–44. discussion 44.
    1. Pujades Ma C, Camacho C, Perez-Calatayud J, et al. The use of nomograms in LDR-HDR prostate brachytherapy. J Contemp Brachytherapy. 2011;3:121–124.
    1. King CR. LDR vs HDR brachytherapy for localized prostate cancer- the view from radiobiological models. Brachytherapy. 2002;1:219–228.
    1. Leibel SA, Phillips TL. Textbook of Radiation Oncology. Second Edition. 2004. pp. 988–1000. Chapter 45.
    1. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098–1104.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj